Illumina Launches the VeriSeq™ NIPT Solution in Europe

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the VeriSeq™ NIPT Solution, a CE-IVD marked next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT), including CE-IVD marked library prep and analysis software, which enables laboratories in the European Union to bring efficient, highly accurate NIPT in-house. The automated comprehensive solution allows laboratories... Read more

Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research

Agreement expands Kailos’ use of market-leading next-generation sequencing solutions March 21, 2017 06:00 AM Pacific Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. (NASDAQ: ILMN). Under the terms of the... Read more

Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases

SAN DIEGO and HERCULES, Calif. — January 9, 2017 — Illumina, Inc. (NASDAQ: ILMN) and Bio‑Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers... Read more